An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
about
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonistZyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of actionSex Differences in Kappa Opioid Receptor Function and Their Potential Impact on AddictionDose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humansNeuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin APeptide kappa opioid receptor ligands: potential for drug development.Practical considerations for the clinical use of buprenorphine.Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.Advances in opioid antagonist treatment for opioid addiction.Evaluation of opioid modulation in major depressive disorderBuprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.Factors associated with the transition from abuse to dependence among substance abusers: implications for a measure of addictive liability.New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewIn vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptorC7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.Agonist-antagonist combinations in opioid dependence: a translational approachNovel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 1: effects of cleavage conditions and N-terminal functionalityThe effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behaviorBuprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Development of κ opioid receptor antagonists.The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208Naltrexone alters the processing of social and emotional stimuli in healthy adultsCocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviorsStructure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.Dynorphin A analogs for the treatment of chronic neuropathic pain.Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in miceKappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants.Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.Naltrexone and buprenorphine combination in the treatment of opioid dependence.Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactions.Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.
P2860
Q24535736-4268BF88-9042-4CD6-B497-ED2052BB0316Q24642144-4152611A-1BE0-4CEF-BBAF-18E250B47AFBQ26770785-2B2411F8-E8C1-4963-BC1C-D450424C047DQ30447153-6E820C89-8962-4C75-A6A1-A82461F83593Q30467220-A7D84F69-82E8-48FB-BF6C-18B13EAC2F2DQ33442900-9F3A219C-0258-4E05-9E21-95DC4D14DFC2Q33774853-8617BEC4-1EAC-411F-A964-D366486B5BABQ33842725-C0548FD3-18C5-470E-8144-B901D6287337Q34262649-033F3C00-519E-4AEE-92D9-F871B1ED7949Q34454397-12C7845E-1C3E-4CAB-ADCA-BAA4BA2430DBQ34517116-D7526C5C-BEAC-415D-ABEE-488E357CCE30Q34536352-0B7631A9-3342-490C-B3A3-39A43B0BE34CQ34952233-6F5DA29A-5A5F-46C7-A1F9-56E6A4FCDE06Q35084340-26365236-BB6E-4A7B-AFF0-BBCFDAF37B56Q35182618-C46DE4D6-DF30-4654-B19E-731676B7B895Q35669185-CB1E6B1B-2A20-4BE8-BA12-36E53FB1A05DQ35733030-EF7C0B79-0950-4AF7-88D2-D437AECF5213Q35848930-601C938D-8404-4FD7-A67E-6C6569549C34Q36104010-91C8A8CE-5800-4DDC-A3E1-F7DB6C090A5EQ36138467-BA3250FD-18CB-404C-AA01-20C2D245506AQ36143025-25EAD8C9-97CD-457B-805D-C5760863D6D7Q36157077-EA732952-C01F-491B-B89B-DCA34C9C3B98Q36296493-BB59A3A5-2B13-4445-8E38-B1268E3E53D5Q36394429-ED5DB724-76E9-40A6-8DC1-A427590D020FQ36728154-EBD26C6E-C702-4001-87F8-1586B952B977Q36836438-9295AD14-8231-412C-AC13-62922897C874Q36887197-3844364B-6AE2-49E0-A6B1-43C43D65E36FQ37119755-6D288B63-BDAE-4949-A404-3286523CA8F5Q37140536-85B95765-0E90-4A28-8255-0414CA39C7ABQ37483673-89DAA23B-0BAD-4EF1-B398-4E4EF6736965Q37589122-3D309F24-E918-41F6-8DB5-761BAFA526E6Q38677168-8808D6E1-D0AD-4708-AB5B-2D614F44E6CBQ38715846-280C6ACE-E94E-4EB6-89DD-04EE806D42A5Q41537125-5009606E-F221-4BF8-99F4-B6F6B1B42262Q41639865-825DBBA9-79B4-4232-A949-A67F6290DC57Q41657869-DF965D9D-3F82-4577-801D-D396238E7B97Q44348482-B9EF7A53-8A5E-4D40-B6BC-C485BA236654Q44351532-92469617-1B28-4A87-9FD4-07E76CFF614CQ44781088-B8AD7282-BB52-47C5-8F0B-0EEE508F969FQ47753097-BC2883E0-A135-43D8-92B1-1490133F49F5
P2860
An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
An open-label study of a funct ...... reatment of opioid dependence.
@ast
An open-label study of a funct ...... reatment of opioid dependence.
@en
type
label
An open-label study of a funct ...... reatment of opioid dependence.
@ast
An open-label study of a funct ...... reatment of opioid dependence.
@en
prefLabel
An open-label study of a funct ...... reatment of opioid dependence.
@ast
An open-label study of a funct ...... reatment of opioid dependence.
@en
P2093
P1476
An open-label study of a funct ...... reatment of opioid dependence.
@en
P2093
Eichmiller PR
Gorelick DA
Heishman SJ
Liberto JG
Rothman RB
P304
P356
10.1016/S0740-5472(99)00074-4
P577
2000-04-01T00:00:00Z